GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (STU:APS) » Definitions » Short Percentage of Float

Asarina Pharma AB (STU:APS) Short Percentage of Float


View and export this data going back to 2020. Start your Free Trial

What is Asarina Pharma AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Asarina Pharma AB's Short Percentage of Float

For the Biotechnology subindustry, Asarina Pharma AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asarina Pharma AB's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Asarina Pharma AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Asarina Pharma AB's Short Percentage of Float falls into.


Asarina Pharma AB (STU:APS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (STU:APS) » Definitions » Short Percentage of Float
Comparable Companies
XSAT:ALTE OSTO:CYXO OSTO:DIABIO OSTO:REDW OSTO:PHARM OSTO:AMNI XSAT:PHAL OSTO:LIDDS OSTO:SPAGO OSTO:CLINE B OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ASAP:Sweden
Address
Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65
Website
https://www.asarinapharma.com
Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB (STU:APS) Headlines

No Headlines